|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Dalteparin#Warnings]] |
| {{Dalteparin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| ===Increased Risk of Hemorrhage===
| |
| | |
| Spinal or epidural hematomas can occur with the associated use of [[low molecular weight heparins]] or heparinoids and neuraxial (spinal/epidural) [[anesthesia]] or [[spinal puncture]]. The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as [[NSAIDs]], with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity , [see Boxed Warning and Adverse Reactions (6.2) and Drug Interactions (7)].
| |
| | |
| Use FRAGMIN with extreme caution in patients who have an increased risk of [[hemorrhage]], such as those with severe uncontrolled hypertension, [[bacterial endocarditis]], congenital or acquired bleeding disorders, active ulceration and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal or ophthalmological surgery. Fragmin may enhance the risk of bleeding in patients with thrombocytopenia or platelet defects; severe liver or kidney insufficiency, hypertensive or diabetic retinopathy, and recent gastrointestinal bleeding. Bleeding can occur at any site during therapy with FRAGMIN.
| |
| | |
| ===Thrombocytopenia===
| |
| | |
| [[Heparin-induced thrombocytopenia]] can occur with the administration of FRAGMIN. The incidence of this complication is unknown at present. In clinical practice, cases of thrombocytopenia with thrombosis, amputation and death have been observed.[See Contraindications (4)] Closely monitor thrombocytopenia of any degree.
| |
| | |
| In FRAGMIN clinical trials supporting non-cancer indications, platelet counts of < 50,000/mm3 occurred in < 1% of patients.
| |
| | |
| In the clinical trial of patients with cancer and acute symptomatic [[venous thromboembolism]] treated for up to 6 months in the FRAGMIN treatment arm, platelet counts of < 100,000/mm3 occurred in 13.6% of patients, including 6.5% who also had platelet counts less than 50,000/mm3. In the same clinical trial, thrombocytopenia was reported as an adverse event in 10.9% of patients in the FRAGMIN arm and 8.1% of patients in the OAC arm. FRAGMIN dose was decreased or interrupted in patients whose platelet counts fell below 100,000/mm3.
| |
| | |
| ===Benzyl Alcohol===
| |
| | |
| Each multiple-dose vial of FRAGMIN contains benzyl alcohol as a preservative. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants. Because benzyl alcohol may cross the placenta, use caution when administering FRAGMIN preserved with benzyl alcohol to pregnant women. If anticoagulation with FRAGMIN is needed during pregnancy, use preservative-free formulations, where possible. [See Use in Specific Populations (8.1)].
| |
| | |
| ===Laboratory Tests===
| |
| | |
| Periodic routine complete blood counts, including platelet count, blood chemistry, and stool occult blood tests are recommended during the course of treatment with FRAGMIN. When administered at recommended prophylaxis doses, routine coagulation tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) are relatively insensitive measures of FRAGMIN activity and, therefore, unsuitable for monitoring the anticoagulant effect of FRAGMIN. Anti-Factor Xa may be used to monitor the anticoagulant effect of FRAGMIN, such as in patients with severe renal impairment or if abnormal coagulation parameters or bleeding occurs during FRAGMIN therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FRAGMIN (DALTEPARIN SODIUM) INJECTION [EISAI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5cd4a8e-14c0-440b-b453-9f3d3250c951 | publisher = | date = | accessdate = 2 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Heparin group]]
| |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |